Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from a hematopoietic stem cell. The normal counterpart is a precursor plasmacytoid dendritic cell. In the 2016 World Health Organization classification it is classified as a distinct entity among myeloid neoplasms.[1][